Schedule 13D ownership disclosure
IKENA ONCOLOGY INC
COMMON STOCK · CUSIP: 45175G108
Event date: 2025-06-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 8,008,913.00 · Class: 16.71%
- ORBIMED CAPITAL GP VI LLCReported CIK 0001682115
Shares: 7,768,790.00 · Class: 16.21%
- OrbiMed Genesis GP LLCReported CIK 0001808744
Shares: 240,123.00 · Class: 0.50%
- ORBIMED CAPITAL LLCReported CIK 0001157524
Shares: 1,572,638.00 · Class: 3.28%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000619
- Form type
- SCHEDULE 13D/A
- Filer
- ImageneBio, Inc.
- CIK
- CIK 1835579
- Filed
- Jun 18, 2025
- Reporting period
- Jun 14, 2025
- Description
- Schedule 13D beneficial ownership